• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer
Catholic Review

Catholic Review

Inspiring the Archdiocese of Baltimore

Menu
  • Home
  • News
        • Local News
        • World News
        • Vatican News
        • Obituaries
        • Featured Video
        • En Español
        • Sports News
        • Official Clergy Assignments
        • Schools News
  • Commentary
        • Contributors
          • Question Corner
          • George Weigel
          • Elizabeth Scalia
          • Michael R. Heinlein
          • Effie Caldarola
          • Guest Commentary
        • CR Columnists
          • Archbishop William E. Lori
          • Rita Buettner
          • Christopher Gunty
          • George Matysek Jr.
          • Mark Viviano
          • Father Joseph Breighner
          • Father Collin Poston
          • Amen Columns
  • Entertainment
        • Events
        • Movie & Television Reviews
        • Arts & Culture
        • Books
        • Recipes
        • CR for Kids
  • About Us
        • Contact Us
        • Our History
        • Meet Our Staff
        • Photos to own
        • Shop
        • CR Media platforms
        • Electronic Edition
        • Subscribe
  • Advertising
  • Kids
  • Radio/Podcasts
        • Catholic Review Radio
        • Protagonistas de Fe
        • In God’s Image
  • News Tips
  • Subscribe
Sen. Josh Hawley, R-Mo., speaks during a press conference on the U.S. Food and Drug Administration's abortion drug policies on Capitol Hill in Washington Jan. 14, 2026. Sen. Hawley announced March 11 he has introduced legislation in the Senate that would ban mifepristone, a drug commonly, but not exclusively, used for first trimester abortion. (OSV News photo/Reuters, Nathan Howard)

Sen. Hawley introduces bill to revoke FDA approval of abortion pill

March 12, 2026
By Kate Scanlon
OSV News
Filed Under: News, Respect Life, World News

WASHINGTON (OSV News) — Sen. Josh Hawley, R-Mo., announced March 11 he has introduced legislation in the Senate that would ban mifepristone, a drug commonly, but not exclusively, used for first trimester abortion.

The Safeguarding Women from Chemical Abortion Act, if enacted, would revoke the Food and Drug Administration’s approval of the drug.

However, the path forward for the legislation was not clear, as President Donald Trump indicated as a candidate for president in 2024 he would veto a national abortion ban if one reached his desk. Abortion restrictions have failed to gain traction in Congress since the Supreme Court’s 2022 Dobbs v. Jackson Women’s Health Organization decision, which overturned its previous precedent that held abortion as a constitutional right.

“We’ve known for years that mifepristone is risky, but it’s really just in the last few years that we’ve learned this drug is inherently dangerous, and it’s inherently prone to abuse,” Hawley said in remarks at the Capitol March 11.

Proponents of the drug argue it is statistically safe for a woman to take, and attempts to restrict it are an attempt to ban abortion outright. In contrast, opponents argue there are significant risks to those who take it, particularly outside of medical settings, in addition to ending the life of an unborn child.

Hawley argued, “Only Congress can address this situation.”

“Only Congress can withdraw the FDA approval rendered way back in the Clinton administration for this drug that has proved to be inherently dangerous and inherently prone to abuse. Only Congress can act,” he argued.

FDA officials pledged mifepristone would undergo a safety review. However, the status and timeline of the FDA’s review is unclear.

Meanwhile, the Trump administration has asked multiple judges to pause state lawsuits seeking to roll back Biden administration-era eased restrictions on mifepristone, arguing those court cases would interfere with its review. In one such filing in Louisiana, the Justice Department said such reviews often take one year.

The FDA also recently approved a new generic form of the drug.

Mifepristone, the first of two drugs used in a medication-based abortion, was approved by the FDA in 2000, and gained the moniker “the abortion pill.” Medication abortions, sometimes called chemical abortions, account for the majority of abortions in the U.S., according to multiple studies.

Pro-life opponents of mifepristone have pushed the Trump administration to roll back eased restrictions on the drug implemented by the Biden administration. Over a year into Trump’s second term, the Trump administration has thus far left that regulation in place.

The Catholic Church teaches that all human life is sacred from conception to natural death and, as such, opposes direct abortion. Church leaders have called for restricting mifepristone’s use in abortion, while noting that the drug’s more recent usage in medical protocols for miscarriage care, where an unborn child has passed away of natural causes, would be a morally legitimate scenario.

Read More Respect Life

Lawsuit continues to challenge Biden-era regulation adding abortion to pregnant worker protections

Supreme Court leaves in place mail-order distribution of mifepristone during legal challenge

New Senate bill aims to protect privacy for charitable donors following pregnancy center case

Makary out as FDA commissioner after tumultuous tenure, pro-life criticism

As Planned Parenthood defunding nears expiration, USCCB pro-life chair backs bill to block funds

‘Congratulations!’ What moms want to hear in facing challenging or unexpected pregnancies

Copyright © 2026 OSV News

Print Print

Primary Sidebar

Kate Scanlon

Click here to view all posts from this author

For the latest news delivered twice a week via email or text message, sign up to receive our free enewsletter.

| MOST POPULAR |

  • Archdiocese of Baltimore files new proposed plan for Chapter 11 reorganization
  • Archbishop Lori ordains 12 transitional deacons
  • Parish scarred by clergy abuse creates memorial for survivors
  • Catholic high school students experience professions firsthand
  • Archdiocese of Baltimore names teachers of the year

| Latest Local News |

Loyola receives $500,000 grant for York Road trust-building initiative 

Sacred Heart 6th grader wins Archdiocese of Baltimore Catholic Schools Spelling Bee

Catholic high school students experience professions firsthand

Archbishop Lori ordains 12 transitional deacons

Radio Interview: Saying yes to God’s plan

| Latest World News |

What exactly is an encyclical?

Border bishops have ‘grave concerns’ about $72 billion immigration enforcement funding package

The liturgy sustains the faithful, renewing them in their faith, mission, pope says

Pope Leo XIV urges confirmation candidates to ask Holy Spirit for gift of perseverance

Vance ‘looking forward to reading’ Pope Leo’s AI encyclical

| Catholic Review Radio |

Footer

Our Vision

Real Life. Real Faith. 

Catholic Review Media communicates the Gospel and its impact on people’s lives in the Archdiocese of Baltimore and beyond.

Our Mission

Catholic Review Media provides intergenerational communications that inform, teach, inspire and engage Catholics and all of good will in the mission of Christ through diverse forms of media.

Contact

Catholic Review
320 Cathedral Street
Baltimore, MD 21201
443-524-3150
mail@CatholicReview.org

 

Social Media

  • Facebook
  • Instagram
  • Twitter
  • YouTube

Recent

  • What exactly is an encyclical?
  • Loyola receives $500,000 grant for York Road trust-building initiative 
  • Border bishops have ‘grave concerns’ about $72 billion immigration enforcement funding package
  • Home viewing roundup: What’s available to stream and what’s on horizon
  • The liturgy sustains the faithful, renewing them in their faith, mission, pope says
  • Pope Leo XIV urges confirmation candidates to ask Holy Spirit for gift of perseverance
  • Sacred Heart 6th grader wins Archdiocese of Baltimore Catholic Schools Spelling Bee
  • Vance ‘looking forward to reading’ Pope Leo’s AI encyclical
  • Lawsuit continues to challenge Biden-era regulation adding abortion to pregnant worker protections

Search

Membership

Catholic Media Assocation

Maryland-Delaware-DC Press Association

The Associated Church Press

© 2026 CATHOLIC REVIEW MEDIA, ALL RIGHTS RESERVED